Clinical trials: Luminal B
Breast Cancer
Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
PELICAN is a randomised phase II trial that aims to evaluate the efficacy and safety of paclitaxel plus pembrolizumab relative to paclitaxel alone, in patients with locally advanced or metastatic ER-positive, HER2-negative…
- Trial name
- PELICAN (NCT03841747)
- Testing
- Pembrolizumab, Paclitaxel
- Sponsor
- Queen Mary University of London
Luminal B
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1.
- Trial name
- Neo-CheckRay (NCT03875573)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Oleclumab
- Where
- 7 sites in Belgium, France
- Volunteers
- 147 people
- Sponsor
- Jules Bordet Institute
Susceptibility, Genetic, Chemotherapy Effect
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
We plan to carry out a prospective, randomized, open phase III clinical trial which sponsored by the Tianjin Medical University Cancer Hospital and Institute.
- Trial name
- NCT03359694
- Testing
- DT group, ET group, NX group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Triple Negative Breast Cancer
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
The study has a phase Ib and a phase II part. The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Luminal B
- Trial name
- B-IMMUNE (NCT03356860)
- Testing
- Paclitaxel, Epirubicin, Cyclophosphamide
- Where
- 4 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Grand Hôpital de Charleroi
Metastatic Breast Cancer, ER-positive Breast Cancer
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
The objective of this trial, DBCG R25, will be to evaluate the effect of trastuzumab-deruxtecan versus standard of care on progression-free survival (PFS) in first-line for patients with non-Luminal A, ER-positive/HER2-negative…
- Conditions
- Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched
- Trial name
- DISCORDANT (NCT06585969)
- Testing
- Trastuzumab deruxtecan (T-DXd), Ribociclib with ET, Abemaciclib with ET
- Sponsor
- Danish Breast Cancer Cooperative Group
Primary Breast Cancer
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
We aimed to evaluate the noninferiority of short-term anthracycline-free chemotherapy (TC, six cycles of docetaxel and cyclophosphamide) or short-term anthracycline-based chemotherapy (CEF-T, three cycles of…
- Trial name
- NCT01314833
- Testing
- Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel
- Where
- China
- Volunteers
- 1,570 people
- Sponsor
- Fudan University
Triple Negative, HER2+, Luminal B Breast Tumors (Stages II-III)in Female Patients
CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.
This project aims to determine whether biopsy using radiofrequency is a procedure suitable for this patient selection. Findings from biopsy will be correlated with the conventional surgery ones.
- Trial name
- NCT01984866
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
Nipple Aspirate Fluid in Detecting Breast Cancer
This trial studies nipple aspirate fluid in detecting breast cancer. Nipple aspirate fluid may better detect breast cancer earlier than current methods used for screening such as mammograms and breast examinations.
- Conditions
- Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
- Trial name
- NCT03715959
- Testing
- Aspiration of Breast, Biospecimen Collection
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B, premenopausal breast cancer patients stage II-IIIA.
- Trial name
- GIADA (NCT04659551)
- Testing
- Epirubicin, Cyclophosphamide, Triptorelin
- Where
- 5 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Breast Cancer
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.
CORALLEEN is a two-arm, randomized, multicentric study in postmenopausal women with primary HR+/HER2 negative Luminal B breast cancer that will explore if the combination of ribociclib with letrozole offers clinical benefit at…
- Trial name
- CORALLEEN (NCT03248427)
- Testing
- Ribociclib, Letrozole 2.5mg, Doxorubicin
- Where
- 21 sites in Spain
- Volunteers
- 106 people
- Sponsor
- SOLTI Breast Cancer Research Group
HER-2 Negative Breast Cancer
Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer
This is an open-label, single arm, two-stage Simon Design study for women with LuminalB/HER-2 Negative Breast Cancer treated with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin.
- Trial name
- NCT03799692
- Testing
- Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Fudan University
Breast Adenocarcinoma, Luminal B Breast Cancer
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas
RATIONALE: The primary treatment for estrogen receptor-positive breast cancer relies on estrogen receptor inhibitors. However, responses to hormonal therapy can vary significantly, especially in luminal B breast cancer…
- Trial name
- H/ACA-ER (NCT06805084)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
VENTANA is a "window-of-opportunity" trial that will explore whether, similar to CDK4/6 inhibitors, Oral Metronomic Vinorelbine in combination with Letrozole induces a superior anti-proliferative effect than Letrozole alone.
- Trial name
- NCT02802748
- Testing
- Oral Vinorelbine, Letrozole
- Where
- 10 sites in Spain
- Volunteers
- 60 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes
This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with…
- Trial name
- NCT04403984
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Hellenic Cooperative Oncology Group